<DOC>
	<DOCNO>NCT01720719</DOCNO>
	<brief_summary>The purpose study compare impact atorvastatin 20mg qd Vitamin E 300mg qd therapy liver fat content patient type 2 diabetes associate high LDL-C non-alcoholic fatty liver disease .</brief_summary>
	<brief_title>Atorvastatin Versus Vitamin E Treatment Non-alcoholic Fatty Liver Disease</brief_title>
	<detailed_description>Previous study preliminary proven safety efficacy atorvastatin tablet treatment Non-alcoholic fatty liver disease ( NAFLD ) .However , sample size study small study use B-ultrasound CT semi-quantitative determination liver fat content . The defect evaluation method seriously affect accuracy study . Also , antioxidant agent propose potentially effective treatment . Vitamin E potent antioxidant compound , test pediatric NAFLD absence side effect . Conflicting result report clinical trial , child adult . The project intend adopt advanced proton magnetic resonance spectroscopy ( 1H-MRS ) non-invasively precisely determine liver fat content understand change liver fat content treatment atorvastatin tablet Vitamin E NAFLD patient abnormal lipid metabolism type 2 diabetes . We also intend compare therapeutic effect atorvastatin Vitamin E treatment NAFLD .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . Sign inform consent involvement trialrelated activity ( trialrelated activity refers measure adopt normal treatment patient ) . 2 . Male female , 18 year ≤ age ≤ 70 year . 3 . Type 2 diabetes ( already diagnose oral glucose tolerance test ( OGTT ) test find comply 2003 ADA diagnostic criterion diabetes ) . 4 . Patients nonalcoholic fatty liver disease , MRS measurement liver fat content &gt; 10 % . 5 . Without take lipidlowering drug Vitamin E 3 month enrollment . 6 . LDLC ≥ 2.6mmol/L . 7 . No heavy drinking history ( alcohol intake : male &lt; 20g/d , female &lt; 10g/d ) . 8 . HBsAg ( ) , HCVAb ( ) . 9 . 18.5 kg/m2 ≤ BMI ≤ 40kg/m2 1 . Liver , renal dysfunction ( ALT AST 2.5 time high upper limit normal , total bilirubin ( TB ) 1.5 time high upper limit normal , Cr ≥ 115μmol/L ) . 2 . Muscle enzyme 2 time high normal . 3 . Type 1 diabetes , gestational diabetes , special type diabetes . 4 . Has use drug may affect liver fat content , glucocorticoid thyroxine within one month trial . 5 . With hypothyroidism , hypothalamicpituitary dysfunction , sleep apnea syndrome , acanthosis nigricans , polycystic ovary syndrome , psoriasis , colorectal adenoma polyp disease NAFLD easily associate . 6 . Previous history chronic viral hepatitis , autoimmune liver disease , druginduced liver disease liver disease cause genetic factor . 7 . Severe uncontrolled hypertension ( treat , sit rest systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 100mmHg ) . 8 . Pregnancy , breastfeeding , plan pregnancy , failure take adequate contraceptive measure ( contraception measure include sterilization , intrauterine device ( IUD ) , oral contraceptive consistent condom use ) . 9 . With intellectual , psychological language barrier , subject fully understand cooperate study . 10 . Any circumstance may affect implementation result study . 11 . Class III Class IV heart disease New York Heart Association ( NYHA ) classification , unstable angina attack myocardial infarction recent 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Non-alcoholic Fatty Liver Disease</keyword>
	<keyword>Dyslipidemias</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>Vitamin E</keyword>
</DOC>